{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:09Z","timestamp":1793727849206,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40257-017-0298-5","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:49:30Z","timestamp":1496364570000},"page":"733-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":181,"title":["Vitiligo: An Update on Pathophysiology and Treatment Options"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3546","authenticated-orcid":false,"given":"Reinhart","family":"Speeckaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"298_CR1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","volume":"65","author":"A Alikhan","year":"2011","unstructured":"Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR2","first-page":"113","volume":"33","author":"PVV Prasad","year":"2003","unstructured":"Prasad PVV, Bhatnagar VK. Medico-historical study of \u201cKilasa\u201d (vitiligo\/leucoderma) a common skin disorder. Bull Indian Inst Hist Med Hyderabad. 2003;33:113\u201327.","journal-title":"Bull Indian Inst Hist Med Hyderabad."},{"key":"298_CR3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2014.155","volume":"150","author":"M-A Yazdani Abyaneh","year":"2014","unstructured":"Yazdani Abyaneh M-A, Griffith R, Falto-Aizpurua L, Nouri K. The dark history of white spots. JAMA Dermatol. 2014;150:936.","journal-title":"JAMA Dermatol."},{"key":"298_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/JID.2015.398","volume":"136","author":"C Salzes","year":"2016","unstructured":"Salzes C, Abadie S, Seneschal J, Whitton M, Meurant J-M, Jouary T, et al. The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136:52\u20138.","journal-title":"J Invest Dermatol."},{"key":"298_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15199","author":"Y Lai","year":"2016","unstructured":"Lai Y, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2016. doi: 10.1111\/bjd.15199 .","journal-title":"Br J Dermatol"},{"key":"298_CR6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMcp0804388","volume":"360","author":"A Ta\u00efeb","year":"2009","unstructured":"Ta\u00efeb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009;360:160\u20139.","journal-title":"N Engl J Med"},{"key":"298_CR7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1365-2133.2010.10202.x","volume":"164","author":"D-Y Kim","year":"2011","unstructured":"Kim D-Y, Oh SH, Hann S-K. Classification of segmental vitiligo on the face: clues for prognosis. Br J Dermatol. 2011;164:1004\u20139.","journal-title":"Br J Dermatol"},{"key":"298_CR8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjd.12652","volume":"170","author":"N Geel van","year":"2014","unstructured":"van Geel N, Bosma S, Boone B, Speeckaert R. Classification of segmental vitiligo on the trunk. Br J Dermatol. 2014;170:322\u20137.","journal-title":"Br J Dermatol"},{"key":"298_CR9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaad.2010.08.031","volume":"65","author":"K Ezzedine","year":"2011","unstructured":"Ezzedine K, Gauthier Y, L\u00e9aut\u00e9-Labr\u00e8ze C, Marquez S, Bouchtnei S, Jouary T, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol. 2011;65:965\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR10","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/jdv.13663","volume":"30","author":"JE Lommerts","year":"2016","unstructured":"Lommerts JE, Schilder Y, de Rie MA, Wolkerstorfer A, Bekkenk MW. Focal vitiligo: long-term follow-up of 52 cases. J Eur Acad Dermatol Venereol. 2016;30:1550\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2016.07.060","volume":"75","author":"JE Lommerts","year":"2016","unstructured":"Lommerts JE, Teulings H-E, Ezzedine K, van Geel N, Hartmann A, Speeckaert R, et al. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. J Am Acad Dermatol. 2016;75:1198\u2013204.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR12","first-page":"1762","volume":"84","author":"S Laureti","year":"1999","unstructured":"Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison\u2019s disease underestimated? J Clin Endocrinol Metab. 1999;84:1762.","journal-title":"J Clin Endocrinol Metab"},{"key":"298_CR13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2133.2012.11198.x","volume":"167","author":"C Vrijman","year":"2012","unstructured":"Vrijman C, Kroon MW, Limpens J, Leeflang MMG, Luiten RM, van der Veen JPW, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167:1224\u201335.","journal-title":"Br J Dermatol"},{"key":"298_CR14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jdv.12169","volume":"28","author":"N Geel van","year":"2014","unstructured":"van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune\/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28:741\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208\u201314.","journal-title":"Pigment Cell Res"},{"key":"298_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fgene.2016.00003","volume":"7","author":"C Shen","year":"2016","unstructured":"Shen C, Gao J, Sheng Y, Dou J, Zhou F, Zheng X, et al. Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci. Front Genet. 2016;7:3.","journal-title":"Front Genet."},{"key":"298_CR17","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","volume":"362","author":"Y Jin","year":"2010","unstructured":"Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362:1686\u201397.","journal-title":"N Engl J Med"},{"key":"298_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/138920207783591690","volume":"8","author":"SC Gough","year":"2007","unstructured":"Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8:453\u201365.","journal-title":"Curr Genomics"},{"key":"298_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng.2272","volume":"44","author":"Y Jin","year":"2012","unstructured":"Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012;44:676\u201380.","journal-title":"Nat Genet"},{"key":"298_CR20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.2011.321","volume":"132","author":"RA Spritz","year":"2012","unstructured":"Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132:268\u201373.","journal-title":"J Invest Dermatol."},{"key":"298_CR21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jdv.12171","volume":"28","author":"R Speeckaert","year":"2014","unstructured":"Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014;28:755\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2133.2012.11111.x","volume":"167","author":"N Geel van","year":"2012","unstructured":"van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L, et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012;167:1017\u201324.","journal-title":"Br J Dermatol"},{"key":"298_CR23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0019-5154.185704","volume":"61","author":"RW Doss","year":"2016","unstructured":"Doss RW, El-Rifaie A-AA, Abdel-Wahab AM, Gohary YM, Rashed LA. Heat shock protein-70 expression in vitiligo and its relation to the disease activity. Indian J Dermatol. 2016;61:408\u201312.","journal-title":"Indian J Dermatol."},{"key":"298_CR24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/pcmr.12208","volume":"27","author":"JA Mosenson","year":"2014","unstructured":"Mosenson JA, Flood K, Klarquist J, Eby JM, Koshoffer A, Boissy RE, et al. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res. 2014;27:209\u201320.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","volume":"27","author":"A Bertolotti","year":"2014","unstructured":"Bertolotti A, Boniface K, Vergier B, Mossalayi D, Taieb A, Ezzedine K, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27:398\u2013407.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.033","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Voet S, Hoste E, van Geel N. S100B is a potential disease activity marker in non-segmental vitiligo. J Invest Dermatol. 2017. doi: 10.1016\/j.jid.2017.01.033 .","journal-title":"J Invest Dermatol."},{"key":"298_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15151","author":"JY Kim","year":"2016","unstructured":"Kim JY, Lee EJ, Seo J, Oh SH. Impact of HMGB1 on melanocytic survival and its involvement in the pathogenesis of vitiligo. Br J Dermatol. 2016. doi: 10.1111\/bjd.15151 .","journal-title":"Br J Dermatol"},{"key":"298_CR28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","volume":"16","author":"Y Gauthier","year":"2003","unstructured":"Gauthier Y, Cario Andre M, Ta\u00efeb A. A critical appraisal of vitiligo etiologic theories: is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16:322\u201332.","journal-title":"Pigment Cell Res"},{"key":"298_CR29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/jid.2015.25","volume":"135","author":"RY Wagner","year":"2015","unstructured":"Wagner RY, Luciani F, Cario-Andr\u00e9 M, Rubod A, Petit V, Benzekri L, et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol. 2015;135:1810\u20139.","journal-title":"J Invest Dermatol."},{"key":"298_CR30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2133.2001.03952.x","volume":"144","author":"K Jimbow","year":"2001","unstructured":"Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol. 2001;144:55\u201365.","journal-title":"Br J Dermatol"},{"key":"298_CR31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.12691","volume":"170","author":"J Marie","year":"2014","unstructured":"Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo\/nonsegmental vitiligo progression. Br J Dermatol. 2014;170:816\u201323.","journal-title":"Br J Dermatol"},{"key":"298_CR32","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1222808110","volume":"110","author":"CB Levandowski","year":"2013","unstructured":"Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1\u03b2 processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA. 2013;110:2952\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"298_CR33","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG Boorn van den","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TAM, van der Veen JPW, Bos JD, Melief CJM, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129:2220\u201332.","journal-title":"J Invest Dermatol."},{"key":"298_CR34","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.aaa1292","volume":"346","author":"Y Maeda","year":"2014","unstructured":"Maeda Y, Nishikawa H, Sugiyama D, Ha D, Hamaguchi M, Saito T, et al. Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals. Science. 2014;346:1536\u201340.","journal-title":"Science"},{"key":"298_CR35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","volume":"26","author":"M Dwivedi","year":"2013","unstructured":"Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R. Decreased regulatory T-cells and CD4(+) \/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res. 2013;26:586\u201391.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1684\/ejd.2013.2023","volume":"23","author":"MA Elela","year":"2013","unstructured":"Elela MA, Hegazy RA, Fawzy MM, Rashed LA, Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients. Eur J Dermatol. 2013;23:350\u20135.","journal-title":"Eur J Dermatol."},{"key":"298_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","volume":"424","author":"MK Tembhre","year":"2013","unstructured":"Tembhre MK, Sharma VK, Sharma A, Chattopadhyay P, Gupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta. 2013;424:27\u201332.","journal-title":"Clin Chim Acta"},{"key":"298_CR38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ijd.12392","volume":"54","author":"M Vaccaro","year":"2015","unstructured":"Vaccaro M, Cannav\u00f2 SP, Imbesi S, Cristani M, Barbuzza O, Tigano V, et al. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int J Dermatol. 2015;54:672\u20134.","journal-title":"Int J Dermatol"},{"key":"298_CR39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00403-016-1675-2","volume":"308","author":"M Vaccaro","year":"2016","unstructured":"Vaccaro M, Cicero F, Mannucci C, Calapai G, Spatari G, Barbuzza O, et al. IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Arch Dermatol Res. 2016;308:527\u201330.","journal-title":"Arch Dermatol Res"},{"key":"298_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cyto.2016.12.014","volume":"91","author":"S Bhardwaj","year":"2017","unstructured":"Bhardwaj S, Rani S, Srivastava N, Kumar R, Parsad D. Increased systemic and epidermal levels of IL-17A and IL-1\u03b2 promotes progression of non-segmental vitiligo. Cytokine. 2017;91:153\u201361.","journal-title":"Cytokine"},{"key":"298_CR41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","volume":"28","author":"L Zhou","year":"2015","unstructured":"Zhou L, Shi Y-L, Li K, Hamzavi I, Gao T-W, Huggins RH, et al. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015;28:324\u20139.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR42","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M-W, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223ra23.","journal-title":"Sci Transl Med."},{"key":"298_CR43","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","volume":"137","author":"AF Rezk","year":"2017","unstructured":"Rezk AF, Kemp DM, El-Domyati M, El-Din WH, Lee JB, Uitto J, et al. Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression. J Invest Dermatol. 2017;137:1126\u201334.","journal-title":"J Invest Dermatol."},{"key":"298_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.02.012","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Ongenae K, van Geel N. Alterations of CXCL12 in serum of vitiligo patients. J Invest Dermatol. 2017. doi: 10.1016\/j.jid.2017.02.012 .","journal-title":"J Invest Dermatol."},{"key":"298_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.013","author":"S Li","year":"2016","unstructured":"Li S, Zhu G, Yang Y, Jian Z, Guo S, Dai W, et al. Oxidative stress drives CD8(+)T cells skin trafficking in vitiligo via CXCL16 upregulation by activating the unfolded protein response in keratinocytes. J Allergy Clin Immunol. 2016. doi: 10.1016\/j.jaci.2016.10.013 .","journal-title":"J Allergy Clin Immunol."},{"key":"298_CR46","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1523-1747.ep12492607","volume":"97","author":"R Harning","year":"1991","unstructured":"Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97:1078\u201380.","journal-title":"J Invest Dermatol."},{"key":"298_CR47","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1468-3083.2012.04501.x","volume":"27","author":"MW Kroon","year":"2013","unstructured":"Kroon MW, Kemp EH, Wind BS, Krebbers G, Bos JD, Gawkrodger DJ, et al. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J Eur Acad Dermatol Venereol. 2013;27:1172\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cei.12168","volume":"174","author":"A Ruiz-Arg\u00fcelles","year":"2013","unstructured":"Ruiz-Arg\u00fcelles A, Garc\u00eda-Carrasco M, Jimenez-Brito G, S\u00e1nchez-Sosa S, P\u00e9rez-Romano B, Garc\u00e9s-Eisele J, et al. Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol. 2013;174:229\u201336.","journal-title":"Clin Exp Immunol"},{"key":"298_CR49","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","volume":"135","author":"C Regazzetti","year":"2015","unstructured":"Regazzetti C, Joly F, Marty C, Rivier M, Mehul B, Reiniche P, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J Invest Dermatol. 2015;135:3105\u201314.","journal-title":"J Invest Dermatol."},{"key":"298_CR50","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/jid.2013.235","volume":"133","author":"T Yamada","year":"2013","unstructured":"Yamada T, Hasegawa S, Inoue Y, Date Y, Yamamoto N, Mizutani H, et al. Wnt\/\u03b2-catenin and kit signaling sequentially regulate melanocyte stem cell differentiation in UVB-induced epidermal pigmentation. J Invest Dermatol. 2013;133:2753\u201362.","journal-title":"J Invest Dermatol."},{"key":"298_CR51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0923-1811(01)00134-7","volume":"27","author":"C Tu","year":"2001","unstructured":"Tu C, Zhao D, Lin X. Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci. 2001;27:178\u201382.","journal-title":"J Dermatol Sci"},{"key":"298_CR52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.12013","volume":"168","author":"N Geel van","year":"2013","unstructured":"van Geel N, Speeckaert R, Melsens E, Toelle SP, Speeckaert M, De Schepper S, et al. The distribution pattern of segmental vitiligo: clues for somatic mosaicism. Br J Dermatol. 2013;168:56\u201364.","journal-title":"Br J Dermatol"},{"key":"298_CR53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","volume":"23","author":"NAC Geel van","year":"2010","unstructured":"van Geel NAC, Mollet IG, De Schepper S, Tjin EPM, Vermaelen K, Clark RA, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010;23:375\u201384.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4103\/0019-5154.119949","volume":"58","author":"VR Attili","year":"2013","unstructured":"Attili VR, Attili SK. Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinical mosaicism. Indian J Dermatol. 2013;58:433\u20138.","journal-title":"Indian J Dermatol."},{"key":"298_CR55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2133.2011.10650.x","volume":"166","author":"N Geel van","year":"2012","unstructured":"van Geel N, Mollet I, Brochez L, Dutr\u00e9 M, De Schepper S, Verhaeghe E, et al. New insights in segmental vitiligo: case report and review of theories. Br J Dermatol. 2012;166:240\u20136.","journal-title":"Br J Dermatol"},{"key":"298_CR56","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.14356","volume":"174","author":"M Whitton","year":"2016","unstructured":"Whitton M, Pinart M, Batchelor JM, Leonardi-Bee J, Gonzalez U, Jiyad Z, et al. Evidence-based management of vitiligo: summary of a Cochrane systematic review. Br J Dermatol. 2016;174:962\u20139.","journal-title":"Br J Dermatol"},{"key":"298_CR57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","volume":"159","author":"DJ Gawkrodger","year":"2008","unstructured":"Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051\u201376.","journal-title":"Br J Dermatol"},{"key":"298_CR58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb A, Alomar A, B\u00f6hm M, Dell\u2019anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5\u201319.","journal-title":"Br J Dermatol"},{"key":"298_CR59","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","volume":"51","author":"NB Silverberg","year":"2004","unstructured":"Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004;51:760\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.14283","volume":"174","author":"N Geel van","year":"2016","unstructured":"van Geel N, Desmedt V, De Schepper S, Boone B, Lapeere H, Speeckaert R. Cessation of spread as a treatment objective in vitiligo: perception from the patients\u2019 point of view. Br J Dermatol. 2016;174:922\u20134.","journal-title":"Br J Dermatol"},{"key":"298_CR61","first-page":"1532","volume":"134","author":"MD Njoo","year":"1998","unstructured":"Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998;134:1532\u201340.","journal-title":"Arch Dermatol"},{"key":"298_CR62","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/pcmr.12480","volume":"29","author":"H Jung","year":"2016","unstructured":"Jung H, Oh E-S. FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression. Pigment Cell Melanoma Res. 2016;29:434\u201343.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/pcmr.12443","volume":"29","author":"H Jung","year":"2016","unstructured":"Jung H, Chung H, Chang SE, Kang D-H, Oh E-S. FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. Pigment Cell Melanoma Res. 2016;29:199\u2013209.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR64","doi-asserted-by":"crossref","unstructured":"Ho N, Pope E, Weinstein M, Greenberg S, Webster C, Krafchik BR. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71% vs. clobetasol propionate 0\u00b705% in childhood vitiligo. Br J Dermatol. 2011;165:626\u201332.","DOI":"10.1111\/j.1365-2133.2011.10351.x"},{"key":"298_CR65","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1468-3083.2009.03138.x","volume":"23","author":"S Radakovic","year":"2009","unstructured":"Radakovic S, Breier-Maly J, Konschitzky R, Kittler H, Sator P, Hoenigsmann H, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol. 2009;23:951\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"298_CR66","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1529-8019.2008.00198.x","volume":"21","author":"T Lotti","year":"2008","unstructured":"Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, et al. Targeted and combination treatments for vitiligo: comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008;21(Suppl. 1):S20\u20136.","journal-title":"Dermatol Ther"},{"key":"298_CR67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1755-148X.2011.00922.x","volume":"25","author":"N Geel van","year":"2012","unstructured":"van Geel N, Speeckaert R, Mollet I, De Schepper S, De Wolf J, Tjin EPM, et al. In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res. 2012;25:57\u201365.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4632.2008.03660.x","volume":"47","author":"KU Schallreuter","year":"2008","unstructured":"Schallreuter KU, Kr\u00fcger C, W\u00fcrfel BA, Panske A, Wood JM. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol. 2008;47:743\u201353.","journal-title":"Int J Dermatol"},{"key":"298_CR69","first-page":"461","volume":"150","author":"G Leone","year":"2015","unstructured":"Leone G, Paro Vidolin A. Effect of an antioxydant cream versus placebo in patients with vitiligo in association with excimer laser: a pilot randomized, investigator-blinded, and half-side comparison trial. G Ital Dermatol Venereol. 2015;150:461\u20136.","journal-title":"G Ital Dermatol Venereol."},{"key":"298_CR70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0781.2006.00222.x","volume":"22","author":"TS Anbar","year":"2006","unstructured":"Anbar TS, Westerhof W, Abdel-Rahman AT, El- Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed. 2006;22:157\u201363.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"298_CR71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0190-9622(00)90133-6","volume":"42","author":"MD Njoo","year":"2000","unstructured":"Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","volume":"56","author":"E Nicolaidou","year":"2007","unstructured":"Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1468-3083.2007.01980.x","volume":"21","author":"JC Sitek","year":"2007","unstructured":"Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol. 2007;21:891\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR74","doi-asserted-by":"crossref","unstructured":"Caron-Schreinemachers A-LDB, Kingswijk MM, Bos JD, Westerhof W. UVB 311\u00a0nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol. 2005;85:24\u20136.","DOI":"10.1080\/00015550410022203"},{"key":"298_CR75","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavali\u00e9","year":"2015","unstructured":"Cavali\u00e9 M, Ezzedine K, Fontas E, Montaudi\u00e9 H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970\u20134.","journal-title":"J Invest Dermatol."},{"key":"298_CR76","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1468-3083.2007.02283.x","volume":"21","author":"A Bhatnagar","year":"2007","unstructured":"Bhatnagar A, Kanwar A, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40257-015-0164-2","volume":"17","author":"C Lopes","year":"2016","unstructured":"Lopes C, Trevisani VFM, Melnik T. Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. Am J Clin Dermatol. 2016;17:23\u201332.","journal-title":"Am J Clin Dermatol"},{"key":"298_CR78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0140-6736(91)90083-2","volume":"338","author":"B Lindel\u00f6f","year":"1991","unstructured":"Lindel\u00f6f B, Sigurgeirsson B, Tegner E, Lark\u00f6 O, Johannesson A, Berne B, et al. PUVA and cancer: a large-scale epidemiological study. Lancet. 1991;338:91\u20133.","journal-title":"Lancet"},{"key":"298_CR79","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","volume":"44","author":"S Radakovic-Fijan","year":"2001","unstructured":"Radakovic-Fijan S, F\u00fcrnsinn-Friedl AM, H\u00f6nigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR80","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000439563","volume":"232","author":"J Lee","year":"2016","unstructured":"Lee J, Chu H, Lee H, Kim M, Kim DS, Oh SH. A retrospective study of methylprednisolone mini-pulse therapy combined with narrow-band UVB in non-segmental vitiligo. Dermatology (Basel). 2016;232:224\u20139.","journal-title":"Dermatology (Basel)."},{"key":"298_CR81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dth.12172","volume":"28","author":"R Colucci","year":"2015","unstructured":"Colucci R, Dragoni F, Conti R, Pisaneschi L, Lazzeri L, Moretti S. Evaluation of an oral supplement containing Phyllanthus emblica fruit extracts, vitamin E, and carotenoids in vitiligo treatment. Dermatol Ther. 2015;28:17\u201321.","journal-title":"Dermatol Ther"},{"key":"298_CR82","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-3083.2006.02132.x","volume":"21","author":"MA Middelkamp-Hup","year":"2007","unstructured":"Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21:942\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR83","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1365-2133.2010.10014.x","volume":"163","author":"N Geel van","year":"2010","unstructured":"van Geel N, Wallaeys E, Goh BK, De Mil M, Lambert J. Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus. Br J Dermatol. 2010;163:1186\u201393.","journal-title":"Br J Dermatol"},{"key":"298_CR84","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/exd.13072","volume":"25","author":"NB Goldstein","year":"2016","unstructured":"Goldstein NB, Koster MI, Hoaglin LG, Wright MJ, Robinson SE, Robinson WA, et al. Isolating RNA from precursor and mature melanocytes from human vitiligo and normal skin using laser capture microdissection. Exp Dermatol. 2016;25:805\u201311.","journal-title":"Exp Dermatol"},{"key":"298_CR85","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","volume":"14","author":"R Speeckaert","year":"2015","unstructured":"Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n\u2019t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev. 2015;14:332\u201340.","journal-title":"Autoimmun Rev"},{"key":"298_CR86","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2011.04002.x","volume":"25","author":"EJ Nordal","year":"2011","unstructured":"Nordal EJ, Guleng GE, R\u00f6nnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right\/left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR87","doi-asserted-by":"crossref","unstructured":"Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005;153:701\u20135.","DOI":"10.1111\/j.1365-2133.2005.06899.x"},{"key":"298_CR88","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1468-3083.2010.03876.x","volume":"25","author":"KM AlGhamdi","year":"2011","unstructured":"AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011;25:749\u201357.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"298_CR89","first-page":"384","volume":"15","author":"C Hossain","year":"2016","unstructured":"Hossain C, Porto DA, Hamzavi I, Lim HW. Camouflaging agents for vitiligo patients. J Drugs Dermatol. 2016;15:384\u20137.","journal-title":"J Drugs Dermatol"},{"key":"298_CR90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","volume":"28","author":"V Eleftheriadou","year":"2015","unstructured":"Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, et al. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res. 2015;28:363\u20139.","journal-title":"Pigment Cell Melanoma Res."},{"key":"298_CR91","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","volume":"136","author":"N Geel van","year":"2016","unstructured":"van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, et al. Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative. J Invest Dermatol. 2016;136:978\u201384.","journal-title":"J Invest Dermatol."},{"key":"298_CR92","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2016.09.008","volume":"43","author":"JP Strassner","year":"2016","unstructured":"Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol. 2016;43:81\u20138.","journal-title":"Curr Opin Immunol"},{"key":"298_CR93","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110\u20132.","journal-title":"JAMA Dermatol."},{"key":"298_CR94","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74:370\u20131.","journal-title":"J Am Acad Dermatol"},{"key":"298_CR95","doi-asserted-by":"crossref","unstructured":"Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054\u201360.e1.","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"298_CR96","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2016.12399","volume":"316","author":"K Ezzedine","year":"2016","unstructured":"Ezzedine K, Whitton M, Pinart M. Interventions for vitiligo. JAMA. 2016;316:1708\u20139.","journal-title":"JAMA"},{"key":"298_CR97","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/dth.12383","volume":"29","author":"IV Korobko","year":"2016","unstructured":"Korobko IV, Lomonosov KM. A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. Dermatol Ther. 2016;29:437\u201341.","journal-title":"Dermatol Ther"},{"key":"298_CR98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42\u201350.","journal-title":"JAMA Dermatol."},{"key":"298_CR99","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamadermatol.2014.4848","volume":"151","author":"T Passeron","year":"2015","unstructured":"Passeron T. Indications and limitations of afamelanotide for treating vitiligo. JAMA Dermatol. 2015;151:349\u201350.","journal-title":"JAMA Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-017-0298-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T22:14:24Z","timestamp":1659046464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-017-0298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s40257-017-0298-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}